Axillary surgery in women with sentinel node-positive operable breast cancer: a systematic review with meta-analyses by Schmidt‑Hansen, Mia et al.
Schmidt‑Hansen et al. SpringerPlus  (2016) 5:85 
DOI 10.1186/s40064‑016‑1712‑9
REVIEW
Axillary surgery in women with sentinel 
node‑positive operable breast cancer: a 
systematic review with meta‑analyses
Mia Schmidt‑Hansen1*, Nathan Bromham1, Elise Hasler1 and Malcolm W. Reed2,3
Abstract 
 Traditionally, women with node‑positive operable breast cancer have received complete axillary lymph node dissec‑
tion (ALND), which is associated with significant morbidity, but recently less invasive alternatives have been explored. 
We conducted a systematic review of randomised controlled trials assessing alternative approaches to axillary surgery 
in patients with pathologically‑confirmed sentinel node‑positive operable breast cancer. We searched on 16/3/15 the 
Specialized Register of the Cochrane Breast Cancer group; CENTRAL; MEDLINE; PreMEDLINE; EMBASE; WHO Interna‑
tional Clinical Trials Registry Portal; ClinicalTrials.gov; conference proceedings from ASCO and the San Antonio Breast 
Cancer meetings; checked reference lists and contacted authors to identify relevant studies. Double, independent 
study sifting, extraction, appraisal and summarising were undertaken using standard Cochrane Collaboration meth‑
odology. We included three studies (2020 patients) comparing ALND with sentinel lymph node dissection (SLND) to 
SLND alone, and two studies (1899 patients) comparing ALND to axillary radiotherapy (aRT). No differences in survival 
or recurrence were observed between ALND and SLND or aRT, but morbidity may have been increased in ALND, and 
all the results were subject to different biases, such as recruitment bias, performance bias, and outcome‑reporting 
bias. Whilst it is encouraging that there appears to be no adverse effect on recurrence or survival, it will be appropriate 
to confirm these findings and provide additional data confirming quality of life effects and long term outcomes.
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Background
Current NICE Guidance for patients treated in the 
United Kingdom National Health Service makes the fol-
lowing recommendations:
  • Offer further axillary treatment to patients with early 
invasive breast cancer who:
• have macrometastases or micrometastases shown 
in a sentinel lymph node.
•  have a preoperative ultrasound-guided needle 
biopsy with histologically proven metastatic cancer.
 The preferred technique is axillary lymph node dis-
section (ALND) because it gives additional staging 
information.
•  Do not offer further axillary treatment to patients 
found to have only isolated tumour cells in their 
sentinel lymph nodes. These patients should be 
regarded as lymph node-negative (NICE 2009).
This guidance was last updated in 2009 and is currently 
under review. Since then a number of studies have evalu-
ated whether all patients identified as having metastatic 
breast cancer in the axillary sentinel nodes require comple-
tion axillary lymph node dissection (ALND) and whether 
radiotherapy might be an effective alternative to ALND 
in patients where further treatment is recommended fol-
lowing the identification of a positive axillary node. Tra-
ditionally complete or partial excision of axillary lymph 
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nodes was common practice in the surgical treatment of 
patients with early breast cancer regardless of the presence 
or absence of metastatic disease. This provided informa-
tion on likely prognosis and guidance on the selection of 
appropriate adjuvant therapies, including chemotherapy 
and radiotherapy, following mastectomy. Concerns relat-
ing to the morbidity associated with ALND, particularly 
arm swelling (lymphoedema), shoulder stiffness and neu-
ropathic pain, resulted in the development of targeted pro-
cedures (sentinel lymph node biopsy [SNLB], axillary node 
sampling) designed to stage the axilla, with ALND only 
recommended for those patients where positive evidence 
of metastatic disease was identified. These techniques 
were shown to be associated with less morbidity in the 
group undergoing SLNB alone without any clear adverse 
impact on overall survival or disease free survival (Brom-
ham et  al.: Axillary staging for operable primary breast 
cancer (Cochrane Review), submitted). However, for those 
patients with a positive SLNB a second procedure (ALND) 
was required in most cases although preoperative molecu-
lar assessment or other techniques such as imprint cytology 
have been utilised in some centres to facilitate completion 
axillary node clearance as a single procedure in those found 
to have metastatic spread to the sentinel node/s.
The increased use of molecular markers (e.g. HER2, 
Oestrogen and Progesterone receptor status) has resulted 
in a reduced reliance on numerical axillary node status 
for adjuvant therapy decision-making and resulted in 
the proposal that ALND may not be indicated in patients 
with (limited) axillary node disease and, similarly, the 
proposal that radiotherapy might be associated with 
fewer side effects and similar outcomes to ALND.
Objectives
To assess in a systematic review conducted and reported 
according to the PRISMA guidelines (Moher et al. 2009) 
the benefits and harms of alternative approaches to axil-
lary surgery (including omitting such surgery altogether) 
in terms of overall survival; disease-free survival; local, 
regional and distant recurrences; short-term adverse 
events; and long-term complications in patients with 
pathologically-confirmed sentinel node-positive operable 
breast cancer.
Methods
We included randomised controlled trials in women 
with clinically-defined operable primary breast cancer 
with a positive sentinel lymph node, comparing the fol-
lowing interventions as part of the initial surgical treat-
ment of early breast cancer: ALND versus no axillary 
surgery; and ALND versus axillary radiotherapy without 
ALND; and reporting the following outcomes: Over-
all survival; disease-free survival; disease control in the 
axilla; breast cancer recurrence; adverse events; long-
term complications; and quality-of-life. For all studies 
involving full axillary surgery or axillary sampling, the 
number of nodes removed and method of node analy-
sis was recorded where available, to indicate whether 
an adequate sampling or clearance procedure was 
performed.
The search strategy consisted of the following searches 
(see Additional file 1 for full search strategies):
1. The Specialized Register of the Cochrane Breast Can-
cer group on 16 March 2015. Details of the sources 
and search strategies used to populate this register 
are described in the Group’s module in The Cochrane 
Library (http://onlinelibrary.wiley.com/o/cochrane/
clabout/articles/BREASTCA/frame.html) Studies 
coded as “AXILLARY NODE(S)”, “EARLY BREAST 
CANCER”, “LOCALLY ADVANCED BREAST 
CANCER”, “PSYCHOSOCIAL”, or “SURGERY” on 
the specialised register has been extracted for consid-
eration;
2. The Cochrane Central Register of Controlled Trials 
(CENTRAL) (The Cochrane Library, issue 2 on 16 
March 2015);
3. MEDLINE via OvidSP (2007–12 March 2015) PreM-
EDLINE via OvidSP (12 March 2015) and EMBASE 
via OvidSP (2002–12 March 2015). We used a vali-
dated filter to identify reports of randomised con-
trolled trials in the initial search of MEDLINE (Lefe-
bvre and Clarke 2001) and for the updated searches 
used the revised filter (Lefebvre et al. 2011); we used 
the Scottish Intercollegiate Guidelines Network RCT 
filter for Embase (http://www.sign.ac.uk/methodol-
ogy/filters.html);
4. The World Health Organisation International Clini-
cal Trials Registry Portal (WHO ICTRP) and Clini-
calTrials.gov for prospectively registered and ongoing 
trials, both on 16 March 2015;
5. The conference proceedings from the American Soci-
ety of Clinical Oncology (ASCO) 41st–50th Annual 
Meetings (2005–2014) via the Journal of Clinical 
Oncology (http://jco.ascopubs.org/site/meetings) 
and the conference proceedings from the San Anto-
nio Breast Cancer (SABCS) 29th-37th Annual Sym-
posium Meetings (2006–2014) via Cancer Research 
web site (http://cancerres.aacrjournals.org/), both on 
12 March 2015;
6. The authors of included or ongoing trials were con-
tacted by e-mail and asked if they knew of any rel-
evant studies, but no further studies were identified. 
The reference lists of the included studies as well as 
published reviews were also checked for relevant 
studies.
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Two authors independently screened the titles and 
abstracts of the records identified in the electronic 
searches, excluding all obviously not relevant studies, 
and examined the full text of potentially eligible trials. If 
required, and possible, additional information was sought 
from the principal investigator of any trial of uncertain 
eligibility. Any discrepancies in eligibility judgements 
were resolved by discussion between the authors.
Study data from each trial were extracted indepen-
dently by two authors with any disagreements in data 
extraction resolved by discussion between the authors. 
The authors of included studies were contacted by e-mail 
and asked to share unpublished data from their trial and 
to clarify any details about their trial that were missing or 
unclear in the published reports.
We assessed the risk of bias in the included studies 
using the standard Cochrane Collaboration methods for 
randomised trials (Higgins et  al. 2011). Selection bias 
(random sequence generation, allocation concealment) 
and reporting bias (selective reporting) were assessed at 
study level, whereas detection bias (blinding of outcome 
assessment) and attrition bias (incomplete outcome data) 
were assessed at outcome level. We did not assess detec-
tion bias for the outcome of survival because this in an 
objective outcome, and we also did not assess perfor-
mance bias because blinding of either healthcare per-
sonnel or patients is not possible with the interventions 
under consideration in this review.
The study data were meta-analysed where possi-
ble. The meta-analysis of time-to-event outcomes in 
Review Manager 5.3 (Nordic Cochrane Centre 2014) 
uses ‘O-E’ and ‘V’ statistics or hazard ratios (HR) for 
each trial. If these were not reported in a given trial we 
calculated them from the available statistics, if possible, 
using the methods described in Tierney (Tierney et  al. 
2007). Heterogeneity in meta-analyses was assessed 
using the I2 statistic. If the I2 value was >50 % we did not 
pool the effect estimates but used the range of effects 
from the individual studies instead. Time-to-event out-
comes, entered as ‘O–E and Variance’ outcomes, were 
statistically synthesised using a fixed-effect model and 
arranged so that HRs  >  1 favoured the ALND group 
and HRs < 1 favoured the comparison group. Dichoto-
mous outcomes were summarised as risk ratios (RR) 
and analysed using a fixed-effects model according to 
the Mantel–Haenszel method and arranged so that 
RRs < 1 favoured the ALND group and RRs > 1 favoured 
the comparison group. All analyses were conducted in 
Review Manager 5.3 (Nordic Cochrane Centre 2014). 
We included only the data available in trial reports or 
through contact with the trial authors. No data imputa-
tion was attempted.
Results
The search identified 7436 unique records, of which 7273 
were excluded based on the title and abstract while the 
full publications of 163 potentially relevant studies were 
examined. Of these, 5 trials reported in 13 publications 
met the inclusion criteria, two studies were still ongo-
ing (comparing ALND to SLNB [NCT01796444 (Wang 
2013), and ALND or axillary radiotherapy [aRT] + adju-
vant treatment versus adjuvant treatment alone [POS-
NOC (Goyal 2014a, b)], respectively) while the remaining 
147 records were excluded because they were: not a ran-
domised trial (n =  20), ineligible population (n =  101), 
unclear intervention (n =  2) and ineligible intervention 
(n  =  24); See also Additional file  2). The five included 
studies compared ALND with sentinel lymph node dis-
section (SLND) to SLND alone [ACOSOG Z0011 (Lucci 
et al. 2007; Olsen and McCall 2008; Giuliano et al. 2010, 
2011); ATTRM-048-13-2000 (Sola et  al. 2013); IBCSG-
23-01 (Galimberti et  al. 2011, 2012, 2013)], and ALND 
to aRT [AMAROS (Straver et al. 2010a, b; Donker et al. 
2014); OTOASOR (Savolt et al. 2013a, b)]. See Tables 1 
and 2 for summary study details and risk-of-bias levels, 
respectively, and Additional file  3 for full study details 
and risk-of-bias assessments. 
ALND with SLND versus SLND
Figure  1 shows that neither overall survival (sum-
mary HR = 0.82, 95 % CI 0.58–1.15; p = 0.25; I2 = 0 %) 
nor disease-free survival (summary HR  =  0.81, 95  % 
CI 0.63–1.04; p  =  0.1; I2  =  0  %) differed between the 
SLND + ALND and SLND treatment groups overall or in 
any of the trials.
Meta-analysis of breast cancer recurrence as a dichoto-
mous outcome, rather than as a time-to-event outcome, 
was undertaken as the data were not reported as time-
to-event outcomes. However, the length of follow-up 
for these data was comparable between the trials (see 
Table  1). These analyses are illustrated in Fig.  2, which 
shows that axillary (summary RR = 0.46, 95 % CI 0.14–
1.49; p = 0.2; I2 = 0 %), local (summary RR = 1.6, 95 % 
CI 0.86–2.97; p  =  0.14; I2  =  0  %), regional (summary 
RR = 0.34, 95 % CI 0.1–1.15; p = 0.08; I2 = 0 %) and dis-
tant breast cancer recurrence (summary RR = 1.31, 95 % 
CI 0.8–2.15; p = 0.28; I2 = 0 %) did not differ between the 
treatment groups.
The ATTRM-048-13-2000 trial did not report on 
short-term adverse events or long term complications 
(Table  3) and is therefore at high risk of reporting bias 
for these outcomes. Inadequate details were reported on 
the selection of patients and the outcome assessment, 
which puts the results at risk of both patient selection 
bias and detection bias (Table  2). Moreover, at baseline 
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the tumours were detected by palpation in more ALND 
than SLND patients. In IBCSG-23-01 the authors did 
not report inferential analyses of the short-term adverse 
events or long-term complications, but the rates of post-
operative infection, sensory neuropathy (any, grade 3–4), 
lymphoedema (any, grade 3–4) and motor neuropathy 
were all numerically higher in the ALND group (Table 3). 
No blinding was undertaken of the outcome assessment, 
which means that the results are at high risk of detection 
bias. Moreover, it was unclear whether the results were 
subject to attrition bias for short-term adverse events and 
long-term complications (Table 2).
Inferential analyses of the rates of short-term adverse 
events were not presented in the ACOSOG Z0011 trial, 
but the rates of wound infection, axillary seromas, axillary 
paresthesias and objective lymphoma are all numerically 
higher in the group that received ALND. The same pattern 
of results was also observed for the long-term complica-
tions of brachial plexus injury, axillary paresthesias, and 
objective and subjective lymphoma at 6 and 12  months; 
and for subjective lymphoma at >12  months (Table  3). 
In this trial it was unclear whether outcome assessment 
was blinded, 30-day short-term adverse event data were 
not reported for all the patients, and the outcome data for 
long-term complications were missing for progressively 
larger proportions of patients in both treatment groups, 
but possibly more so for the SLND group. This in turn 
means that the results must be interpreted with some 
caution because they are at risk of detection bias for all 
outcomes and of attrition bias for the short-term adverse 
events outcome; and for the long-term complications the 
results are at high risk of attrition bias (Table 2). Moreo-
ver, all three trials randomised patients after the results 
of SLND were known, which puts these trials at risk of 
recruitment bias to the extent that patients perceived at 
higher risk (e.g., multiple micrometastatic foci) were not 
invited or chose not to take part in the studies. This is 
because any tendency not to recruit patients perceived to 
be at higher risk would influence the relative performance 
of the interventions in the direction that less extensive 
surgery (SLND) would appear relatively more beneficial 
because the patients who are more likely to benefit from 
more extensive surgery (ALND), that is, patients at higher 
risk, would not be part of the study population. This could 
mean that the results are only applicable to the patients 
seen in clinical practice who meet the inclusion criteria of 
these trials, but are also perceived to be at low risk.
ALND versus aRT
In the AMAROS trial no differences in overall survival, 
disease-free survival, shoulder mobility or quality of life 
were observed between the groups that received ALND 
and aRT (Tables 3, 4). However, the rates of (any clinical 
sign of ) lymphoedema were higher in the ALND group 
at 1, 3 and 5 years. When lymphoedema was defined as 
an arm circumference increase ≥10 %, the rates only dif-
fered significantly at 5 years (Table 3). The trial was open 
label and did not report short-term adverse events or 
long-term complications other than lymphoedema and 
shoulder mobility for which either progressively larger 
or unclear proportions of data were missing, respec-
tively. The results are therefore at high risk of both detec-
tion bias (all outcomes), attrition bias (lymphoedema 
and shoulder mobility) and reporting bias (short-term 
adverse events and long term complications; Table 2).
The OTOASOR trial did also not find any signifi-
cant differences between the treatment groups in over-
all survival, disease-free survival or axillary recurrence 
Fig. 1 Overall survival and disease‑free survival in the studies comparing SLND + ALND to SLND alone
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rates (Table  4), however, the OTOASOR trial did not 
report any morbidity outcomes, which puts the trial at 
risk of reporting bias. Moreover, very little information 
was reported about patient selection and allocation as 
well as about potential blinding of outcome assessment, 
which exposes the results to risk of both selection bias 
(all outcomes) and detection bias (all outcomes) to the 
extent that these were compromised (Table 2). At base-
line, however, more ALND than aRT patients had pT2-3 
tumours. On the other hand, both trials randomised 
patients before sentinel lymph node biopsy, which sug-
gests that the study populations are representative of the 
risk spectrum of those patients seen in clinical practice 
that meet the inclusion criteria of these trials.
Discussion
The evidence for ALND compared to other less inva-
sive strategies for axillary treatment consisted of 5 stud-
ies including 3919 patients and reporting on 2 different 
comparisons: ALND versus aRT and SLND  +  ALND 
versus SLND. None of the included trials found a dif-
ference between the ALND groups and their respec-
tive comparison group in overall  survival, disease-free 
survival or breast cancer recurrence. Two of the studies 
Fig. 2 Breast cancer recurrence in the studies comparing SLND + ALND to SLND alone. Please note the following regarding the data included for 
ACOSOG ZOO11 for regional breast cancer recurrence: Regional recurrence defined as recurrence in the axillary, supraclavicular or internal mam‑
mary nodes. The authors only report local recurrence, axillary recurrence and locoregional recurrence. We have subtracted the local recurrence data 
from locoregional recurrence data to obtain the regional recurrence data, which is equal to the disease recurrence in the axilla data, suggesting that 
no patients recurred in the supraclavicular or internal mammary nodes, provided all these data only count each patient once. An entry of 0 in the 
total number of events column signifies that the study did not report this outcome
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(IBCSG-23-01, ACOSOG Z0011) reported short-term 
adverse events and found that the rates were numeri-
cally higher in the ALND groups than in their respective 
comparison groups (neither study reported inferential 
analyses of these rates). Three of the studies (IBCSG-
23-01, ACOSOG Z0011, AMAROS) reported long-term 
complications and found that lymphoedema tended to 
be higher in the ALND arms, either statistically signifi-
cantly (AMAROS) or numerically (IBCSG-23-01, ACO-
SOG Z0011). Moreover, the rates of sensory neuropathy 
(IBCSG-23-01), motor neuropathy (IBCSG-23-01), bra-
chial plexus injury (ACOSOG Z0011), and axillary par-
esthesias (ACOSOG Z0011) were also numerically higher 
in the ALND groups, although these results were also 
not analysed inferentially. Shoulder mobility and quality 
of life were not found to differ significantly between the 
treatment groups in the only study reporting these out-
comes (AMAROS). These results were, however, subject 
to varying risks of a number of biases, not least detection 
bias, attrition bias, reporting bias and recruitment bias.
Although blinding of the patients and personnel is 
conceivably not feasible in the types of trials included 
in this review, blinding of outcome assessment may be 
undertaken in an effort to minimise the risk of detection 
bias. This bias is more likely to be at play for outcomes 
that are more subjective in evaluation rather than objec-
tive (e.g., survival). We therefore only considered this 
bias for breast cancer recurrence and morbidity. Detec-
tion bias in this context may lead to an overestimation 
of short-term adverse events and long-term complica-
tions in patients who received ALND. Similarly patients 
receiving less extensive axillary treatment may have 
been checked more carefully for breast cancer recur-
rence, because in both cases, the expected results would 
be of more morbidity in ALND and more recurrences 
in the less extensively treated axilla. The risk of attrition 
bias was particularly associated with the morbidity out-
comes. This tended to be because these outcomes were 
assessed in a subset of the trial population. This subgroup 
of patients assessed for adverse events could be system-
atically different from the trial population as a whole, 
especially in the case of assessment for long-term com-
plications when patients may have died or been too sick 
to participate. The morbidity outcomes were also at risk 
of reporting bias in the two studies that did not report 
morbidity at all (ATTRM, OTOASOR), while a third 
study only reported lymphoedema and shoulder mobil-
ity. Given the finding that none of the studies found any 
differences in overall or disease-free survival or in breast 
cancer recurrence, the assessment of treatment-associ-
ated morbidity arguably becomes less important when 
considering which treatment strategy to choose because 
it may be safe to assume that treatment-related morbidity 
will be less in less extensive treatments compared to 
ALND. However, it would still be preferable to be able to 
confirm the veracity of this assumption by being able to 
test it though appropriate analyses. Finally, we were una-
ble to evaluate the risk of patient selection in two studies 
(ATTRM, OTOASOS) because not enough information 
was reported, which is of some concern because patient 
selection bias is a powerful bias that can affect the results 
markedly. Taken together, the risk of the different biases 
discussed above serves to compromise the validity of the 
results to the extent that they are at play and this must be 
borne in mind when considering the results.
Ram and colleagues (Ram et al. 2014) conducted a sys-
tematic review on SNLD alone versus SLND  +  ALND 
and included the same three RCTs included in the cur-
rent review for that comparison, and unsurprisingly their 
conclusions are similar to ours for this comparison. Sys-
tematic reviews by Glechner et  al. (2013) and Li et  al. 
(2015), which included both RCTs and retrospective 
studies, also found no differences in overall survival, dis-
ease-free survival and recurrence between SLND alone 
compared to SLND +  ALND, and higher rates of some 
adverse events associated with SLND + ALND, although 
Glechner et  al. (2013) noted that a number of these 
results are subject to low event rates and/or the poten-
tial influence of different confounding variables and must 
be interpreted with caution. Moreover Li et  al. (2015) 
treated ACOSOG ZOO11 as three RCTs, rather than 
one, which is potentially confusing and certainly at high 
risk of giving an inflated impression of the amount of evi-
dence available. These reviews did not consider ALND 
versus aRT in patients with node-positive operable breast 
cancer, and we have found no other systematic reviews 
on that comparison either.
Implications for practice
The studies described above have resulted in changes in 
guidelines and practice in some countries with imple-
mentation of the findings of the ACOSOG Z0011 study 
in patients who specifically meet the entrance criteria 
in many centres in the USA. This may be partly due to 
the inclusion of a significant number of patients with 
micrometastases in ACOSOG Z011 which are not now 
regarded as an indication for ALND or radiotherapy. 
Similarly there is increased use of axillary radiotherapy as 
an alternative to ALND following positive SLND in sev-
eral European centres. However for the reasons identified 
above and in the following section these studies have not 
resulted in universal changes in practice and further data 
are required to confirm these results. Whilst it is encour-
aging that there appears to be no adverse effect on local, 
regional or distant recurrence or overall survival further 
evidence, particularly in those settings where evidence is 
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lacking (e.g. mastectomy) will be appropriate to confirm 
these findings. At present many clinicians and multidis-
ciplinary teams are interpreting and implementing these 
findings on a case by case basis in patients that strictly 
comply with the inclusion criteria of the relevant stud-
ies and whilst it is hoped this review will provide useful 
confirmation of the appropriateness of this practice, the 
provision of further data will be valuable not least in pro-
viding additional data confirming quality of life effects 
and long term outcomes.
Implications for research
In this review, we only found 3 and 2 studies, respec-
tively, evaluating each of the two target comparisons. 
Moreover, not all of these studies reported all the target 
outcomes. Quality-of-life was for example only reported 
by one of the included trials. We did however identify 
two ongoing trials that with time will contribute further 
data to this area (NCT01796444, POSNOC). These tri-
als notwithstanding, the evidence base cannot be con-
sidered complete at this stage, and it would be preferable 
to see further well-designed and adequately powered 
studies conducted confirming the current results. Fur-
thermore the increased stratification of the treatment 
of the axilla is being explored in further studies in both 
‘low risk’ patients (e.g. no axillary staging) and ‘high risk’ 
patients (e.g. ALND followed by radiotherapy). It appears 
that research in the area of axillary node management in 
breast cancer will continue to drive the evolution from 
a ‘one size fits all’ approach to a more personalised evi-
dence-based approach in future.
Authors’ contributions
MSH and NB conceived the idea for the review, designed the study, screened 
the literature searches, and extracted, appraised and interpreted the data. 
MSH drafted the first version of the article. EH designed and carried out the 
literature searches. MR interpreted the results, wrote the Introduction and the 
Implications for Practice and Research sections. All authors read and approved 
the final manuscript.
Author details
1 National Collaborating Centre for Cancer, Park House, Greyfriars Road, 
Cardiff CF10 3AF, Wales, UK. 2 Brighton and Sussex Medical School, University 
of Sussex, Brighton BN1 9PX, UK. 3 Brighton and Sussex University Teaching 
Hospitals Trust, Brighton, UK. 
Acknowledgements
We would like to thank Dr Laszlo Igali, Consultant Histopathologist, Norfolk 
and Norwich University Hospital, United Kingdom, for help with the transla‑
tion of a trial published in Hungarian.
Additional files
Additional file 1. Full search strategies.
Additional file 2. PRISMA diagram detailing the search results.
Additional file 3. Full study characteristics of the included and ongoing 
studies.
Competing interests
MR is a co‑investigator of POSNOC. Otherwise, the authors declare they have 
no competing interest.
Ethical standards
The research reported in this manuscript comply with the current laws of the 
UK, but were not subject to review by an ethics committee as only data from 
already published studies were used.
Funding
The work reported in this article was not subject to any funding.
Received: 10 January 2016   Accepted: 12 January 2016
References
Donker M, Tienhoven G, Straver ME, Meijnen P, Velde CJH, Mansel RE et al 
(2014) Radiotherapy or surgery of the axilla after a positive sentinel node 
in breast cancer (EORTC 10981‑22023 AMAROS): a randomised, multicen‑
tre, open‑label, phase 3 non‑inferiority trial. Lancet Oncol 15:1303–1310
Galimberti V, Chifu C, Rodriguez Perez S, Veronisi P, Intra M, Botteri E, 
Mastropasqua M, Colleoni M, Luini A, Veronisi U (2011) Positive axillary 
sentinel lymph node: is axillary dissection always necessary? Breast 
20(Supplement 3):S96–S98
Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, Baratella P, Chifu C, 
Sargenti M, Intra M, Gentilini O, Massarut S, Garbay JR, Zgajnar J, Galatius 
H, Recalcati A, Littlejohn D, Bamert M, Price KN, Goldhirsch A, Gelber 
RD, Veronesi U (2012) S3‑1: Update of International Breast Cancer Study 
Group Trial 23‑01 to compare axillary dissection versus no axillary dissec‑
tion in patients with clinically node negative breast cancer and microme‑
tastases in the sentinel node. Cancer Res 71(224, Supplement):S3–1
Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, Baratella P, Chifu C, 
Sargenti M, Intra M, Gentilini O, Mastropasqua MG, Mazzarol G, Massarut 
S, Garbay JR, Zgajnar J, Galatius H, Recalcati A, Littlejohn D, Bamert M, 
Colleoni M, Price KN, Regan MM, Goldhirsch A, Coates AS, Gelber RD, 
Veronesi U, International Breast Cancer Study Group (2013) Axillary 
dissection versus no axillary dissection in patients with sentinel‑node 
micrometastases (IBCSG 23‑01): a phase 3 randomised controlled trial. 
Lancet Oncol 14(4):297–305
Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, 
Saha S, Hunt KK, Morrow M, Ballman K (2010) Locoregional recurrence 
after sentinel lymph node dissection with or without axillary dissec‑
tion in patients with sentinel lymph node metastases: the American 
College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 
252:426–432
Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz 
PW, Leitch AM, Saha S, McCall LM, Morrow M (2011) Axillary dissection vs 
no axillary dissection in women with invasive breast cancer and sentinel 
node metastasis: a randomized clinical trial. JAMA 305:569–575
Glechner A, Wockel A, Gartlehner G, Thaler K, Strobelberger M, Griebler U, 
Kreienberg R (2013) Sentinel lymph node dissection only versus com‑
plete axillary lymph node dissection in early invasive breast cancer: a 
systematic review and meta‑analysis. Eur J Cancer 49(4):812–825
Goyal A (2014a) POSNOC—a randomised trial of armpit (axilla) treatment for 
women with early stage breast cancer (ISRCTN54765244). www.isrctn.
com/ISRCTN54765244. Accessed on 14 July 2015
Goyal A (2014b) POSNOC—POsitive Sentinel NOde: adjuvant therapy alone 
versus adjuvant therapy plus Clearance or axillary radiotherapy: a ran‑
domised controlled trial of axillary treatment in women with early stage 
breast cancer who have metastases in one or two sentinel nodes (Project 
record). Health Technology Assessment Database
Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD et al (2011) 
The Cochrane Collaboration’s tool for assessing risk of bias in randomised 
trials. BMJ 343:d5928
Lefebvre C, Clarke M (2001) Identifying randomised trials. In: Egger M, Davey 
Smith G, Altman DG (eds) Systematic reviews in health care: meta‑analy‑
sis in context. BMJ Publishing Group, London, pp 69–86
Page 13 of 13Schmidt‑Hansen et al. SpringerPlus  (2016) 5:85 
Lefebvre C, Manheimer E, Glanville J (2011) Searching for studies. In: Higgins 
JPT, Green S (eds) Cochrane handbook for systematic reviews of interven‑
tions version 5.1.0. Cochrane Collaboration, Oxford, pp 95–150
Li CZ, Zhang P, Li RW, Wu CT, Zhang XP, Zhu HC (2015) Axillary lymph node 
dissection versus sentinel lymph node biopsy alone for early breast 
cancer with sentinel node metastasis: a meta‑analysis. Eur J Surg Oncol 
41:958–966
Lucci A, McCall LM, Beitsch PD, Whitworth PW, Reintgen DS, Blumencranz PW 
et al (2007) Surgical complications associated with sentinel lymph node 
dissection (SLND) plus axillary lymph node dissection compared with 
SLND alone in the American College of Surgeons Oncology Group Trial 
Z0011. J Clin Oncol 25(24):3657–3663
Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009) Preferred 
reporting items for systematic reviews and meta‑analyses: the PRISMA 
statement. PLoS Med 6:e1000097. doi:10.1371/journal.pmed.1000097
NICE (2009) Early and locally advanced breast cancer: Diagnosis and treat‑
ment. https://www.nice.org.uk/guidance/cg80. Accessed on 6/10/2015
Nordic Cochrane Centre (2014) Review manager (RevMan). The Cochrane Col‑
laboration, Copenhagen
Olson JA Jr, McCall LM (2008) Impact of immediate versus delayed axillary 
node dissection on surgical outcomes in breast cancer patients with 
positive sentinel nodes: results from American College of Surgeons 
Oncology Group trials Z0010 and Z0011. J Clin Oncol 26(21):3530–3535
Ram R, Singh J, McCaig E (2014) Sentinel node biopsy alone versus completion 
axillary node dissection in node positive breast cancer: systematic review 
and meta‑analysis. Int J Breast Cancer. doi:10.1155/2014/513780
Savolt A, Musonda P, Matrai Z, Polgar C, Renyi‑Vamos F, Rubovszky G et al 
(2013a) Optimal treatment of the axilla after positive sentinel lymph node 
biopsy in early invasive breast cancer. Early results of the OTOASOR trial. 
Orv Hetil 154:1934–1942
Savolt A, Polgar C, Musonda P, Matrai Z, Renyi‑Vamos F, Toth L et al (2013b) 
Does the result of completion axillary lymph node dissection influence 
the recommendation for adjuvant treatment in sentinel lymph node‑
positive patients? Clin Breast Cancer 13:364–370
Sola MS, Alberro JA, Fraile M, Santesteban P, Ramos M, Fabregas R, Moral 
A, Ballester B, Vidal S (2013) Complete axillary lymph node dissection 
versus clinical follow‑up in breast cancer patients with sentinel node 
micrometastasis: final results from the multicenter clinical trial AATRM 
048/13/2000. Ann Surg Oncol 20:120–127
Straver ME, Meijnen P, van Tienhoven G, van de Velde CJ, Mansel RE, Bogaerts 
J, Duez N, Cataliotti L, Klinkenbijl JH, Westenberg HA, van der Mijle H, Snoj 
M, Hurkmans C, Rutgers EJ (2010a) Sentinel node identification rate and 
nodal involvement in the EORTC 10981‑22023 AMAROS trial. Ann Surg 
Oncol 17:1854–1861
Straver ME, Meijnen P, van Tienhoven G, van de Velde CJ, Mansel RE, Bogaerts 
J et al (2010b) Role of axillary clearance after a tumor‑positive sentinel 
node in the administration of adjuvant therapy in early breast cancer. J 
Clin Oncol 28(5):731–737
Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods 
for incorporating summary time‑to‑event data into meta‑analysis. Trials 
8(16):1–16
Wang Y (2013) Axillary lymph node dissection versus no dissection in breast 
cancer with positive sentinel lymph node (Z0011‑China). https://clinical‑
trials.gov/ct2/show/NCT01796444. Accessed 14 July 2015
